Open AccessCyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial
Author(s) -
David Nicolás,
Juan Ambrosioni,
Omar Sued,
Merçè Brunet,
María López-Diéguez,
Christian Manzardo,
Fernando Agüero,
Montserrat Tuset,
Montserrat Plana,
Alberto C. Guardo,
María Mar Mosquera,
María Ángeles MuñozFernández,
Miguel Caballero,
M. Ángeles Marcos,
José M. Gatell,
Elisa de Lazzari,
Teresa Gallart,
José M. Miró
Publication year - 2016
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkw462
Subject(s) - viral load , immune system , emtricitabine , lopinavir , medicine , immunology , clinical endpoint , randomized controlled trial , ritonavir , lopinavir/ritonavir , human immunodeficiency virus (hiv) , antiretroviral therapy
Initiating ART during acute/recent HIV-1 infection reduces viral reservoir formation. It has been proposed that, during this phase, the size of the viral reservoir could be further reduced by the association of immunomodulatory therapy with ART. Contradictory results have emerged, however, from two trials evaluating the impact on immune recovery and the viral reservoir of adding cyclosporine A to ART during primary HIV-1 infection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom